Halozyme Therapeutics (HALO) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Repligen (RGEN) over the past year, gaining 68.5% versus a gain of 8.6%. Over five years, HALO leads with a +190.9% price change compared with -38.6% for RGEN. Halozyme Therapeutics is the larger company by market cap ($12.53 billion vs $11.04 billion), about 1.1 times the size.
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.4x vs 65.7x for Repligen). Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | RGEN |
|---|---|---|
| Share price | $110.42 | $173.88 |
| Market cap | $12.53B | $11.04B |
| 1-day change | +0.53% | +6.13% |
| YTD return | +63.21% | -0.01% |
| 1-year return | +68.47% | +8.64% |
| 5-year return | +190.89% | -38.62% |
| P/E ratio (TTM) | 32.29 | 238.19 |
| Forward P/E | 10.39 | 65.68 |
| EPS (TTM) | $3.42 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $738.26M |
| Revenue growth (YoY) | +37.55% | +16.36% |
| Net income (latest FY) | $316.89M | $48.89M |
| Gross margin | 83.62% | 52.32% |
| Operating margin | 33.58% | 7.47% |
| Net margin | 22.69% | 6.62% |
| 52-week high | $116.85 | $198.87 |
| 52-week low | $61.23 | $100.99 |
| Distance from 52-week high | -5.50% | -12.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.84% | +12.12% |
| Average volume | 2.18M | 1.18M |
| Shares outstanding | 113.50M | 63.49M |
| Employees | 423 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HALO has outperformed RGEN by 59.8 percentage points over the past year.
- Repligen trades at a higher earnings multiple (238.2x vs 32.3x trailing P/E).
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus 6.6 cents for Repligen.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs +16.36%).
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
HALO vs RGEN FAQ
Which is bigger, Halozyme Therapeutics or Repligen?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.53B compared with $11.04B for Repligen (RGEN).
Which stock has performed better over the past year, HALO or RGEN?
HALO returned +68.47% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HALO or RGEN?
HALO has the lower trailing P/E at 32.3, versus 238.2 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Halozyme Therapeutics and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.